Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 645727, 12 pages
http://dx.doi.org/10.1155/2015/645727
Research Article

Plumbagin Ameliorates CCl4-Induced Hepatic Fibrosis in Rats via the Epidermal Growth Factor Receptor Signaling Pathway

1Department of Hepatopathy, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, China
2Wenzhou Key Laboratory of Hepatology, Department of Infectious Disease, Hepatology Institute of Wenzhou Medical University, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
3Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
4Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
5Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong

Received 10 July 2015; Revised 25 August 2015; Accepted 26 August 2015

Academic Editor: Yuewen Gong

Copyright © 2015 Si Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Friedman, “Mechanisms of Hepatic Fibrogenesis,” Gastroenterology, vol. 134, no. 6, pp. 1655–1669, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Rosenbloom, S. V. Castro, and S. A. Jimenez, “Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies,” Annals of Internal Medicine, vol. 152, no. 3, pp. 159–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Trebicka, M. Hennenberg, M. Odenthal et al., “Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells,” Journal of Hepatology, vol. 53, no. 4, pp. 702–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Y. Zhang and S. L. Friedman, “Fibrosis-dependent mechanisms of hepatocarcinogenesis,” Hepatology, vol. 56, no. 2, pp. 769–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. V. J. Desmet and T. Roskams, “Cirrhosis reversal: a duel between dogma and myth,” Journal of Hepatology, vol. 40, no. 5, pp. 860–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. I. R. Wanless, E. Nakashima, and M. Sherman, “Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis,” Archives of Pathology and Laboratory Medicine, vol. 124, no. 11, pp. 1599–1607, 2000. View at Google Scholar · View at Scopus
  7. W.-C. Zhou, Q.-B. Zhang, and L. Qiao, “Pathogenesis of liver cirrhosis,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7312–7324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-J. Zhang, X.-K. Meng, C. Dong et al., “Development of a new animal model of liver cirrhosis in swine,” European Surgical Research, vol. 42, no. 1, pp. 35–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. C. Karantonis, G. Gribilas, I. Stamoulis et al., “Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis,” Digestive Diseases and Sciences, vol. 55, no. 2, pp. 276–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-F. Lee, M.-L. Liu, A.-C. Cheng et al., “Pterostilbene inhibits dimethylnitrosamine-induced liver fibrosis in rats,” Food Chemistry, vol. 138, no. 2-3, pp. 802–807, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-Y. Wang, J.-S. Guo, H. Li, S.-L. Liu, and M. A. Zern, “Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CCl(4-) plus ethanol-induced liver cirrhosis in rats,” Liver, vol. 18, no. 3, pp. 180–185, 1998. View at Google Scholar · View at Scopus
  12. S. S. Koca, I. H. Bahcecioglu, O. K. Poyrazoglu, I. H. Ozercan, K. Sahin, and B. Ustundag, “The treatment with antibody of TNF-α reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet,” Inflammation, vol. 31, no. 2, pp. 91–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kawaguchi, I. Sakaida, M. Tsuchiya, K. Omori, T. Takami, and K. Okita, “Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet,” Biochemical and Biophysical Research Communications, vol. 315, no. 1, pp. 187–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Ibañez, N. Solis, M. Pizarro et al., “Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis,” Journal of Gastroenterology and Hepatology, vol. 22, no. 6, pp. 846–851, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. C. H. Tan, D. H. G. Crawford, L. A. Jaskowski et al., “Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury,” Laboratory Investigation, vol. 93, no. 12, pp. 1295–1312, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Liang, B. Zhang, R.-W. Shen et al., “Preventive effect of halofuginone on concanavalin A-induced liver fibrosis,” PLoS ONE, vol. 8, no. 12, Article ID e82232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-S. Wu, X.-X. Piao, D.-M. Piao, Y.-R. Jin, and C.-H. Li, “Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-α,” World Journal of Gastroenterology, vol. 11, no. 1, pp. 122–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Yang, J. Kwon, Y. Popov et al., “Vascular endothelial growth factor promotes fibrosis resolution and repair in mice,” Gastroenterology, vol. 146, no. 5, pp. 1339–1350.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. K.-L. Yang, K.-C. Hung, W.-T. Chang, and E. I. C. Li, “Establishment of an early liver fibrosis model by the hydrodynamics-based transfer of TGF-β1 gene,” Comparative Hepatology, vol. 6, article 9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. B. C. Fuchs, Y. Hoshida, T. Fujii et al., “Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma,” Hepatology, vol. 59, no. 4, pp. 1577–1590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Samarakoon, A. D. Dobberfuhl, C. Cooley et al., “Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species,” Cellular Signalling, vol. 25, no. 11, pp. 2198–2209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Chen, J.-K. Chen, K. Nagai et al., “EGFR signaling promotes TGFβ-dependent renal fibrosis,” Journal of the American Society of Nephrology, vol. 23, no. 2, pp. 215–224, 2012. View at Publisher · View at Google Scholar
  23. S.-C. Chen, J.-Y. Guh, C.-C. Hwang et al., “Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts,” Journal of Cellular Biochemistry, vol. 109, no. 1, pp. 38–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Zeng, A. B. Singh, and R. C. Harris, “The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology,” Experimental Cell Research, vol. 315, no. 4, pp. 602–610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. L. Means, K. C. Ray, A. B. Singh et al., “Overexpression of Heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia,” Gastroenterology, vol. 124, no. 4, pp. 1020–1036, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Cheng, X. Fu, T. Sun, X. Sun, and Z. Sheng, “Expression of epidermal growth factor receptor and related phosphorylation proteins in hypertrophic scars and normal skin,” Chinese Medical Journal, vol. 115, no. 10, pp. 1525–1528, 2002. View at Google Scholar · View at Scopus
  27. N. Liu, J.-K. Guo, M. Pang et al., “Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis,” Journal of the American Society of Nephrology, vol. 23, no. 5, pp. 854–867, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. T.-P. Xu, H. Shen, L.-X. Liu, and Y.-Q. Shu, “Plumbagin from plumbago zeylanica l induces apoptosis in human non-small cell lung cancer cell lines through NF- κB inactivation,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 4, pp. 2325–2331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Checker, D. Sharma, S. K. Sandur, S. Khanam, and T. B. Poduval, “Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes,” International Immunopharmacology, vol. 9, no. 7-8, pp. 949–958, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Sinha, K. Pal, A. Elkhanany et al., “Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo,” International Journal of Cancer, vol. 132, no. 5, pp. 1201–1212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Checker, R. S. Patwardhan, D. Sharma et al., “Plumbagin, a vitamin K3 analogue, abrogates lipopolysaccharide-induced oxidative stress, inflammation and endotoxic shock via NF-kappaB suppression,” Inflammation, vol. 37, no. 2, pp. 542–554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Jia, J. Jing, Y. Bai et al., “Amelioration of experimental autoimmune encephalomyelitis by plumbagin through down-regulation of JAK-STAT and NF-κB signaling pathways,” PLoS ONE, vol. 6, no. 10, Article ID e27006, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Jiang, C. Wang, Y.-Y. Li et al., “Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-β/smad interference,” Journal of Ethnopharmacology, vol. 158, pp. 230–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Chevallier, S. Guerret, P. Chossegros, F. Gerard, and J. Grimaud, “A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies,” Hepatology, vol. 20, no. 2, pp. 349–355, 1994. View at Publisher · View at Google Scholar
  35. L.-P. Wang, J.-Z. Dong, L.-J. Xiong et al., “BMP-7 attenuates liver fibrosis via regulation of epidermal growth factor receptor,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 3537–3547, 2014. View at Google Scholar · View at Scopus
  36. D. Schuppan and N. H. Afdhal, “Liver cirrhosis,” The Lancet, vol. 371, no. 9615, pp. 838–851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. F. J. Eng and S. L. Friedman, “Fibrogenesis. I. New insights into hepatic stellate cell activation: the simple becomes complex,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 279, no. 1, pp. G7–G11, 2000. View at Google Scholar · View at Scopus
  38. A. Anan, E. S. Baskin-Bey, S. F. Bronk, N. W. Werneburg, V. H. Shah, and G. J. Gores, “Proteasome inhibition induces hepatic stellate cell apoptosis,” Hepatology, vol. 43, no. 2, pp. 335–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Zhai, J. Galeotti, J. Liu et al., “An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy,” Circulation Research, vol. 99, no. 5, pp. 528–536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. L.-J. Yu, M.-L. Wu, H. Li et al., “Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells,” Neoplasia, vol. 10, no. 7, pp. 736–744, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Cichocki, H. Szaefer, V. Krajka-Kuźniak, and W. Baer-Dubowska, “The effect of resveratrol and its methylthio-derivatives on EGFR and Stat3 activation in human HaCaT and A431 cells,” Molecular and Cellular Biochemistry, vol. 396, no. 1-2, pp. 221–228, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. M.-Y. Xu, J.-J. Hu, J. Shen et al., “Stat3 signaling activation crosslinking of TGF-β1 in hepatic stellate cell exacerbates liver injury and fibrosis,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1842, no. 11, pp. 2237–2245, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. R. L. Carpenter and H.-W. Lo, “STAT3 target genes relevant to human cancers,” Cancers, vol. 6, no. 2, pp. 897–925, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Sorkin and L. K. Goh, “Endocytosis and intracellular trafficking of ErbBs,” Experimental Cell Research, vol. 314, no. 17, pp. 3093–3106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Kiso, S. Kawata, S. Tamura et al., “Expression of heparin-binding epidermal growth factor-like growth factor in the hepatocytes of fibrotic rat liver during hepatocarcinogenesis,” Journal of Gastroenterology and Hepatology, vol. 14, no. 12, pp. 1203–1209, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Zhang, J. Zhang, X. Jiang et al., “Heparin-binding epidermal growth factor-like growth factor: a hepatic stellate cell proliferation inducer via ErbB receptors,” Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 623–632, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Huang, G. E. Besner, and D. R. Brigstock, “Heparin-binding epidermal growth factor-like growth factor suppresses experimental liver fibrosis in mice,” Laboratory Investigation, vol. 92, no. 5, pp. 703–712, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Takemura, Y. Yoshida, S. Kiso et al., “Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice,” Biochemical and Biophysical Research Communications, vol. 437, no. 2, pp. 185–191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Raghu and D. Karunagaran, “Plumbagin downregulates wnt signaling independent of p53 in human colorectal cancer cells,” Journal of Natural Products, vol. 77, no. 5, pp. 1130–1134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Yong, X.-M. Chen, S. Shen et al., “Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling,” PLoS ONE, vol. 8, no. 8, Article ID e73428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. F. Wei, Molercular Mechanisms of Effect of Plumbagin on Human Hepatic Satellite Cells, Guangxi Medical University, 2011.
  52. S. Sagar, L. Esau, B. Moosa, N. M. Khashab, V. B. Bajic, and M. Kaur, “Cytotoxicity and apoptosis induced by a plumbagin derivative in estrogen positive MCF-7 breast cancer cells,” Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 1, pp. 170–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. K.-H. Xu and D.-P. Lu, “Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo,” Leukemia Research, vol. 34, no. 5, pp. 658–665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Parimala and P. Sachdanandam, “Effect of Plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma,” Molecular and Cellular Biochemistry, vol. 125, no. 1, pp. 59–63, 1993. View at Publisher · View at Google Scholar · View at Scopus